Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Retained Earnings (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Retained Earnings for 5 consecutive years, with -$490.5 million as the latest value for Q4 2025.

  • For Q4 2025, Retained Earnings fell 12.89% year-over-year to -$490.5 million; the TTM value through Dec 2025 reached -$490.5 million, down 12.89%, while the annual FY2025 figure was -$490.5 million, 12.89% down from the prior year.
  • Retained Earnings hit -$490.5 million in Q4 2025 for Kezar Life Sciences, down from -$476.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $107000.0 in Q3 2024 and bottomed at -$490.5 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$230.3 million, with a median of -$239.8 million recorded in 2022.
  • Year-over-year, Retained Earnings surged 100.03% in 2024 and then crashed 444946.73% in 2025.
  • Kezar Life Sciences' Retained Earnings stood at -$180.7 million in 2021, then tumbled by 37.77% to -$248.9 million in 2022, then skyrocketed by 99.95% to -$130000.0 in 2023, then tumbled by 334130.0% to -$434.5 million in 2024, then fell by 12.89% to -$490.5 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$490.5 million, -$476.0 million, and -$464.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.